ProKidney Corp (PROK) is a clinical-stage biotech with no revenue, no approved product, and approximately 204 employees. It has one asset: rilparencel, an autologous cell therapy for chronic kidney disease. The company takes a biopsy of a patient’s diseased kidney, expands and selects specific reparative cells over approximately 12 weeks, then reinjects them into the kidney through a minimally invasive outpatient procedure. No immunosuppression is required.
The Phase 2 data showed an effect size three times the threshold the FDA agreed would be sufficient for approval. The Phase 3 trial is more than half enrolled. Topline data arrives Q2 2027.
The question is not whether the science is interesting. The question is whether an autologous cell therapy — custom-manufactured for each patient, 12 weeks per dose — can be commercialized at a scale that justifies the current enterprise value, let alone a higher one.
What Rilparencel Is and Why It Matters
Chronic kidney disease affects approximately 37 million adults in the United States. Once it progresses to later stages, the available treatments — SGLT2 inhibitors, GLP-1 receptor agonists, mineralocorticoid receptor antagonists — slow the decline but do not stop it. The destination is dialysis or transplant. Dialysis costs Medicare $82,000 per patient per year. Private insurance pays approximately $238,000.
Rilparencel is attempting something fundamentally different. Rather than slowing the decline, the therapy aims to partially reverse it by reinjecting the patient’s own selected renal cells into the damaged kidney. ProKidney estimates that 1.2 to 1.8 million patients in the United States with stage 3b to 4 CKD and type 2 diabetes would be eligible.
The therapy has Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA, which provides expedited development and review.
The Clinical Data
Two trials matter.
REGEN-007 (Phase 2, completed): 53 patients randomized, 49 treated. Open-label, no sham control. Presented at ASN Kidney Week 2025.
| Group | N | Pre-Treatment eGFR Slope | Post-Treatment eGFR Slope | Delta | p-value |
|---|---|---|---|---|---|
| Group 1 (Phase 3 dosing) | 24 | -5.8 | -1.3 | +4.6 | <0.001 |
| Phase 3-eligible subset | 15 | — | — | +5.5 | — |
| Group 2 (trigger-based) | 25 | — | — | +2.6 | 0.085 |
No rilparencel-related serious adverse events in 49 patients.
The FDA agreed that a delta of ≥1.5 mL/min/1.73m²/year would be sufficient for accelerated approval. Group 1 delivered 4.6, more than three times that threshold. The Phase 3-eligible subset showed 5.5.
PROACT 1 (Phase 3, ongoing): Randomized, blinded, sham-controlled — a meaningfully more rigorous design than the open-label Phase 2. Target enrollment of approximately 470 patients across the US, Mexico, and Taiwan, revised down from 685 per a February 2026 8-K (statistical power unchanged). More than 50% enrolled as of fall 2025.
The surrogate endpoint is eGFR slope. The confirmatory endpoint is a time-to-event composite: 40% eGFR decline, eGFR below 15, dialysis, transplant, or renal/cardiovascular death. The FDA confirmed that PROACT 1 alone could support both accelerated and full approval.
Topline surrogate data is expected Q2 2027. Confirmatory data is expected H2 2029.
The transition from open-label to blinded, sham-controlled is the key risk. Effect sizes commonly shrink 30 to 50% in blinded trials. Even at a 50% reduction, the 4.6 delta would fall to 2.3, still above the 1.5 threshold. That margin of safety is the strongest argument in ProKidney’s favor.
The Manufacturing Problem
Rilparencel is an autologous therapy. Each dose is manufactured for a single patient:
- Kidney biopsy at a clinical site
- Tissue shipped to ProKidney’s Winston-Salem, NC facility
- Approximately 12 weeks of cell expansion and selection under cGMP conditions
- Cryopreservation and shipment back to the treatment center
- Percutaneous injection into the kidney
This is not a pill. It is not even a standard biologic. Every unit is custom.
ProKidney paused manufacturing for EU clinical sites in 2023 after a qualified person audit identified GMP documentation deficiencies. Manufacturing resumed for US sites in June 2024 and EU equivalence was obtained in July 2024. The company disclosed plans to transition from a fresh to a cryopreserved formulation for commercial product, which will require comparability studies. Culture media remains the highest manufacturing cost, and the company is working on automation to reduce it.
The closest commercial analogues are CAR-T therapies: Kymriah, Yescarta, Carvykti. These face similar patient-specific manufacturing with 3 to 4 week turnaround times. Years after approval, capacity constraints, turnaround times, and margin compression remain persistent challenges. None has exceeded $2 billion in annual revenue despite targeting large patient populations.
The cautionary tale is Provenge, Dendreon’s autologous dendritic cell therapy for prostate cancer. FDA-approved, scientifically valid, and the company went bankrupt. Manufacturing was too complex and the clinical benefit — approximately four months of survival — was too modest to justify the cost.
Why the Manufacturing Problem Might Not Matter
Provenge failed because the economics did not justify solving the manufacturing problem. Rilparencel’s economics are the opposite.
A one-time treatment priced at $150,000 to $200,000 that prevents dialysis saves $82,000 to $238,000 per year, every year, for the rest of the patient’s life. Every stakeholder in the healthcare system — Medicare, private insurers, hospitals, nephrologists, and patients — is economically motivated to make this therapy available.
That economic alignment is unlike anything in the history of autologous cell therapy. CAR-T competes with chemotherapy regimens that cost a fraction of dialysis. Provenge offered four months against a disease with cheaper alternatives. Rilparencel, if it works, offers an escape from the single most expensive chronic condition in the Medicare system.
The manufacturing complexity is also the moat. Any competitor would need to run their own multi-year clinical program, build their own cGMP autologous cell manufacturing facility, develop their own cell selection and expansion protocols, and navigate their own regulatory pathway. That is a $300 to $500 million, 7 to 10 year barrier to entry. The difficulty of what ProKidney is attempting is precisely what protects it.
Financial Position
As of September 30, 2025:
| Item | Amount |
|---|---|
| Cash and cash equivalents | $95.3M |
| Marketable securities | $176.4M |
| Total liquid assets | $271.7M |
| Total debt | $0 |
| Total liabilities | $33.3M |
| 9-month 2025 operating cash burn | $87.6M |
| Annualized burn rate | ~$117M |
| ATM facility remaining (Jefferies) | ~$175.6M |
| Company-guided cash runway | Mid-2027 |
The company purchased its Winston-Salem manufacturing buildings in November 2024 for $22.5 million. A Greensboro building is held for sale at approximately $19 million. Post-quarter, an additional $17.1 million was raised through the ATM.
The burn rate is trending down from FY2024, when total operating expenses were $183.8 million. Nine-month 2025 operating expenses were $120.3 million ($80.0 million R&D, $40.3 million G&A). ProKidney has enough cash to reach the Q2 2027 data readout without a large capital raise, though continued ATM usage at current share prices will be dilutive.
No strategic partnership or licensing agreement is currently in place. The 10-K states the company does not have any committed external source of funds beyond the ATM. An ex-US licensing deal would be the most accretive path to additional capital, but there is no indication one is being pursued.
Patents
Rilparencel’s intellectual property protection is adequate but not comfortable.
| Category | Expiration |
|---|---|
| Composition of matter | 2029 |
| Formulations | 2031–2038 |
| Quality control methods | 2033–2041 |
| Treatment methods | 2036–2042 |
The 2029 composition-of-matter expiry is uncomfortably close to any realistic commercial launch window. If accelerated approval comes in late 2027 or early 2028, ProKidney would have roughly one to two years of composition-of-matter exclusivity. The method and formulation patents extend protection through the 2030s and 2040s, and a patent term extension may be available, but the near-term IP window is tighter than what most investors would prefer for a first-in-class therapy.
As discussed above, the practical manufacturing barrier likely provides more durable protection than the patent portfolio. Replicating ProKidney’s cell selection and expansion protocols, even after the composition-of-matter patent expires, would require years of development and clinical work.
Valuation
ProKidney is a binary asset. The Phase 3 result determines whether the company is worth billions or pennies. A probability-weighted framework is the only honest way to approach it.
Phase 3 success probability: approximately 55 to 60%. The Phase 2 effect size provides a meaningful margin of safety above the FDA’s agreed threshold, but the open-label design and small sample (n=24 in the key group) warrant caution. Blinded trials commonly reduce effect sizes by 30 to 50%.
Commercialization probability given approval: approximately 55 to 65%. Manufacturing scale-up of an autologous cell therapy is genuinely uncharted territory for kidney disease. The Provenge precedent, while economically dissimilar, demonstrates that approval alone does not guarantee commercial viability.
Combined probability of commercial success: approximately 30 to 35%.
| Scenario | Probability | Enterprise Value | Per Share (~400M diluted at readout) |
|---|---|---|---|
| Phase 3 success, strong commercialization | 25% | $5–7B | $12.50–17.50 |
| Phase 3 success, acquired | 15% | $6–12B | $15.00–30.00 |
| Phase 3 success, weak commercialization | 15% | $2–3B | $5.00–7.50 |
| Phase 3 failure | 45% | ~$150M | $0.35–0.50 |
Probability-weighted value: approximately $5 to $8 per share.
The market at approximately $2.30 per share implies a roughly 20% probability of meaningful success. That discount reflects the binary risk, the manufacturing uncertainty, and the ongoing dilution. Whether that discount is too steep depends on how much weight you place on the Phase 2 effect size margin and the economic incentives that distinguish rilparencel from every prior autologous therapy.
What to Watch
| Catalyst | Why It Matters | Timeline |
|---|---|---|
| PROACT 1 enrollment completion | Fully enrolled trial de-risks the timeline to data readout | H1 2026 |
| Strategic partnership or licensing deal | Validates the science, reduces dilution, de-risks commercialization | Anytime (none currently disclosed) |
| Capital raises / ATM usage | Every dollar raised at $2 dilutes more than a dollar raised at $5 | Ongoing through 2027 |
| PROACT 1 topline surrogate data | The binary event. eGFR slope delta ≥1.5 is the bar. | Q2 2027 |
| Accelerated approval filing | If surrogate data is positive, RMAT designation enables expedited review | H2 2027 |
| Confirmatory endpoint data | Required for full approval; time-to-event composite | H2 2029 |
ProKidney 10-K (March 17, 2025)
ProKidney 10-Q (November 10, 2025)
ProKidney 8-K (February 2, 2026)
ProKidney 8-K (January 12, 2026)
Research and analysis conducted with AI assistance using SEC EDGAR filings as primary sources.